Regeneron and Sanofi's Dupixent Receives FDA Priority Review for Bullous Pemphigoid Treatment, Potentially Becoming First Targeted Option in U.S.

Regeneron and Sanofi's Dupixent is on the brink of potentially becoming the first targeted treatment for bullous pemphigoid in the U.S., with the FDA granting priority review. As the drug continues to demonstrate impressive efficacy and strong market demand, could this be a game-changer for patients and investors alike?